Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents

  • Technology appraisal guidance
  • TA98
  • Published: 

This guidance has been updated and replaced by NICE guideline NG87.